Surface Oncology, Inc.
https://www.surfaceoncology.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Surface Oncology, Inc.
Clasp Launches With $150m To Develop Personalized T-Cell Engagers
Clasp Therapeutics, which emerged from labs at Johns Hopkins University and was incubated by a pair of venture capital investors, plans to achieve a clinical trial readout with its series A cash.
Deal Watch: Coherus Terminates Immuno-Oncology Alliance With Junshi
Plus deals involving Menarini/VenatoRx, Orion/Glykos, Roche/MOMA, Janssen/Elektrofi, Galapagos/BridGene along with 13 other transactions.
Riding US Approval, Junshi, Coherus Swing For PD-1 Combo Therapy Partnerships
Antibodies targeting TIGIT, IL-27, CCR8 and BTLA from the Chinese and US firms are among the first batch of combination candidates expected to expand the indications of anti-PD-1 antibody Loqtorzi beyond the rare condition of nasopharyngeal carcinoma.
Transforming Coherus Adds To IO Pipeline Via Merger With Surface Oncology
Currently battling AbbVie over pricing plans for its Humira biosimilar, Coherus is also looking to become an immuno-oncology player, acquiring two more clinical assets in an all-stock deal.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice